Determination of a novel anticonvulsant drug GIZh-290 in rat plasma by liquid chromatography–tandem mass spectrometry
https://doi.org/10.37489/2587-7836-2021-2-3-10
Abstract
GIZh-290 is a new derivative of 4-phenylpyrrolidone, based on the structures of racetams that combine anticonvulsant and nootropic effects. The method of high-performance liquid chromatography with mass spectrometric detection was developed and validated for the quantitative determination of a new potential anticonvulsant compound GIZh-290 in rat blood plasma. For the extraction of the analyte, liquid-liquid extraction with diethyl ether was used. The method was validated based on its selectivity, linearity, accuracy, precision, and stability. The linearity of the method was confirmed by a high correlation coefficient of 0.999. The percent recovery of GIZh-290 from blood plasma was 79.2 %. The intra- and inter-batch accuracy were 19.32 and 12.14 %. It was found that blood plasma samples containing GIZh-290 can be stored at ambient temperature during the working day.
About the Authors
P. O. Bochkov
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Bochkov Pavel O. - PhD in Biology, Senior Research Officer of laboratory
pharmacokinetics
SPIN code: 5576-8174
Moscow
I. P. Khrustova
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Khrustova Irina P. - Research Laboratory Assistant of laboratory pharmacokinetics
SPIN code: 7304-5377
Moscow
A. A. Litvin
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Litvin Alexander A. - D. Sci. in Biology, Leading researcher of the laboratory
of pharmacokinetics
SPIN code: 6193-5770
Moscow
G. B. Kolyvanov
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Kolyvanov Gennadiy B. - D. Sci. in Biology, Leading researcher of the laboratory
of pharmacokinetics
Moscow
R. V. Shevchenko
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Shevchenko Roman V. - PhD in Medicine, Research Officer of laboratory
pharmacokinetics
SPIN code: 1844-6202
Moscow
V. P. Zherdev
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Zherdev Vladimir P. - D. Sci. in Medicine, professor, Head of laboratory
pharmacokinetics
SPIN code: 2213-9592
Moscow
References
1. Zhmurenko LA, Litvinova SA, Mokrov GV, Kovalev IG, Voronina TA, Nerobkova LN, Gudasheva TA. Synthesis of 4-phenylpyrrolidone derivatives with anticonvulsant and nootropic activity. Pharmaceutical Chemistry Journal. 2019;53(5):20–27. (In Russ). DOI:10.30906/0023-1134-2019-53-5-20-27.
2. Kovalev IG. Search for compounds with anticonvulsant activity among new derivatives of 4-phenylpyrrolidone and coumarin and study of their neurochemical mechanisms of action. [dissertation] Moscow: 2017. (In Russ). Доступно по: https://www.academpharm.ru/images/upload/ru/1510/Dissertaciya_Kovalev_I.G.pdf.
3. Kovalev IG, Voronina TA, Litvinova SA, Zhmurenko LA, Mokrov G V. Comparison of anticonvulsant and mnemotropic properties of new derivatives of 4-phenylpyrrolidone, levetiracetam and piracetam. Russian Journal of Experimental and Clinical Pharmacology. 2017;80(6):13–18. (In Russ). DOI:10.30906/0869-2092-2017-80-6-13-18.
4. Srinivas NR. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed Chromatogr. 2006;20(5):383-414. DOI: 10.1002/bmc.594
5. Hopfgartner G, Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom Rev. 2003;22(3):195–214. DOI: 10.1002/mas.10050.
6. Chao Zhang, Lu Wang, Yan Yang, Yantong Sun, Jie Zhang, Guoqing Li, Jingkai Gu. Validated LC–MS/MS method for the determination of sarpogrelate in humanplasma: Application to a pharmacokinetic and bioequivalence study in Chinese volunteers. J Pharm Biomed Anal. 2010;53(3):546–551. DOI: 10.1016/j.jpba.2010.03.025.
7. Gillespie TA, Winger BE. Mass spectrometry for small molecule pharmaceutical product development: a review. Mass Spectrom Rev. 2011;30(3):479–490. DOI: 10.1002/mas.20289.
8. Lee MS, Kerns EH. LC/MS applications in drug. Mass Spectrom Rev. 1999;18(3-4):187–279. DOI: 10.1002/(SICI)1098-2787(1999)18:3/4<187: AID-MAS2>3.0.CO;2-K.
9. Izuchenie bioekvivalentnosti vosproizvedennykh lekarstvennykh sredstv. Rukovodstvo po ekspertize lekarstvennykh sredstv. Tom I. Moscow: Grif i K; 2013. (In Russ).
10. Rukovodstva po ekspertize lekarstvennykh sredstv Tom I, pravil provedeniya issledovanii bioekvivalentnosti lekarstvennykh preparatov v ramkakh Evraziiskogo ekonomicheskogo soyuza, Sovet Evraziiskoi ekonomicheskoi komissi, reshenie ot 3 noyabrya 2016 №85. (In Russ).
11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER). Bioanalytical method validation. U.S. Government Printing Office: Washington, DC, 2018, 41 P.
12. ЕМА Guideline on bioanalytical method validation. European Medicines Agency. Committee for medicinal products for human use: London, 2011, 23 P.
Review
For citations:
Bochkov P.O., Khrustova I.P., Litvin A.A., Kolyvanov G.B., Shevchenko R.V., Zherdev V.P. Determination of a novel anticonvulsant drug GIZh-290 in rat plasma by liquid chromatography–tandem mass spectrometry. Pharmacokinetics and Pharmacodynamics. 2021;(2):3-10. (In Russ.) https://doi.org/10.37489/2587-7836-2021-2-3-10
Views:
503
Email this article 